Recursion Pharmaceuticals Inc
RXRX
Company Profile
Business description
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Contact
41 South Rio Grande Street
Salt Lake CityUT84101
USAT: +1 385 269-0203
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
600
Stocks News & Analysis
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
stocks
Revenue growth on track for undervalued ASX healthcare stock
Near-term cost growth does not change our long-term view.
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,155.80 | 34.00 | 0.37% |
| CAC 40 | 8,279.84 | 34.05 | 0.41% |
| DAX 40 | 23,900.57 | 93.58 | 0.39% |
| Dow JONES (US) | 48,006.41 | 179.39 | -0.37% |
| FTSE 100 | 10,615.89 | 12.41 | 0.12% |
| HKSE | 25,893.54 | 141.14 | 0.55% |
| NASDAQ | 22,924.60 | 102.19 | 0.45% |
| Nikkei 225 | 56,924.11 | 1,028.79 | 1.84% |
| NZX 50 Index | 13,181.44 | 92.37 | -0.70% |
| S&P 500 | 6,828.85 | 4.19 | 0.06% |
| S&P/ASX 200 | 8,960.60 | 36.20 | 0.41% |
| SSE Composite Index | 3,986.22 | 20.05 | 0.51% |